The short version of evidence base fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-16. Anything still debated is marked as such rather than presented as settled.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Connective tissue neoplasms including sarcomas such as hemangiopericytoma and malignant peripheral nerve sheath tumor in nervous tissue. Congenital diseases include Marfan syndrome and Ehlers–Danlos syndrome. Myxomatous degeneration – a pathological weakening of connective tissue. Mixed connective tissue disease – a disease of the autoimmune system, also undifferentiated connective tissue disease. Systemic lupus erythematosus (SLE) – a major autoimmune disease of connective tissue Scurvy, caused by a deficiency of vitamin C which is necessary for the synthesis of collagen. Fibromuscular dysplasia is a disease of the blood vessels that leads to an abnormal growth in the arterial wall.
Disulfiram inhibits the enzyme acetaldehyde dehydrogenase, which in turn results in buildup of acetaldehyde, a toxic metabolite of ethanol with unpleasant effects. The medication or drug is commonly used to treat alcohol use disorder, and results in immediate hangover-like symptoms upon consumption of alcohol, this effect is widely known as disulfiram effect.
CYP2D6 inhibitors (e.g., fluoxetine, paroxetine and quinidine) can increase exposure for atomoxetine and it can also increase atomoxetine steady-state plasma concentration. Antihypertensive drugs because it can possibly increase the blood pressure β2-agonist e.g. albuterol because it may increase the efficacy of albuterol on the cardiovascular system. Medicines that affect norepinephrine (e.g. venlafaxine, imipramine, mirtazapine) should be used with caution when administered with atomoxetine due to possible synergy or synergistic effects on pharmacodynamic effects. Beware of taking reboxetine in combination with:
Fospropofol (INN), often used as the disodium salt (trade name Lusedra), is an intravenous sedative-hypnotic agent. It is currently approved for use in sedation of adult patients undergoing diagnostic or therapeutic procedures such as endoscopy.
Subsequent to its synthesis in the 1920s, pseudoephedrine was introduced for medical use as a decongestant. Pseudoephedrine is widely available over-the-counter (OTC) in both single-drug and combination preparations. Availability of pseudoephedrine has been restricted starting in 2005 as it can be used to synthesize methamphetamine. Phenylephrine has replaced pseudoephedrine in many over-the-counter oral decongestant products. However, oral phenylephrine appears to be ineffective as a decongestant. In 2023, pseudoephedrine was the 292nd most commonly prescribed medication in the United States, with more than 400,000 prescriptions. In 2023, the combination with brompheniramine and dextromethorphan was the 281st most commonly prescribed medication in the United States, with more than 700,000 prescriptions. In 2023, the combination with loratadine was the 300th most commonly prescribed medication in the United States, with more than 400,000 prescriptions.
Sources: en.wikipedia.org
When inhaled, plutonium can pass into the bloodstream. Once in the bloodstream, plutonium moves throughout the body and into the bones, liver, or other body organs. Plutonium that reaches body organs generally stays in the body for decades and continues to expose the surrounding tissue to radiation and thus may cause cancer. A commonly cited quote by Ralph Nader states that a pound of plutonium dust spread into the atmosphere would be enough to kill 8 billion people. This was disputed by Bernard Cohen, an opponent of the generally accepted linear no-threshold model of radiation toxicity. Cohen estimated that one pound of plutonium could kill no more than 2 million people by inhalation, so that the toxicity of plutonium is roughly equivalent with that of nerve gas. Several populations of people who have been exposed to plutonium dust (e.g. people living down-wind of Nevada test sites, Nagasaki survivors, nuclear facility workers, and "terminally ill" patients injected with Pu in 1945–46 to study Pu metabolism) have been carefully followed and analyzed. Cohen found these studies inconsistent with high estimates of plutonium toxicity, citing cases such as Albert Stevens who survived into old age after being injected with plutonium. "There were about 25 workers from Los Alamos National Laboratory who inhaled a considerable amount of plutonium dust during 1940s; according to the hot-particle theory, each of them has a 99.5% chance of being dead from lung cancer by now, but there has not been a single lung cancer among them."
Prospects of Duterte running for president in the 2016 elections began in February 2015, during which Duterte, then outgoing Mayor of Davao City, re-entered the PDP-Laban party, who courted him to run for president. A month later, Duterte emerged as a preferred presidential candidate in a Pulse Asia poll; tied with Manila mayor and former president Joseph Estrada, Duterte ranked third behind Senator Grace Poe and frontrunner, Vice President Jejomar Binay. In the following months leading to October, however, Duterte repeatedly declined his supporters' clamors for him to run as president because of what he described as a "flawed government system", as well as lack of funds and opposition from his family members—notably, from his daughter Sara. Additionally, Duterte said he will retire from politics after his mayorship ends, but only if Sara runs as mayor. PDP-Laban standard bearer Martin Diño unexpectedly withdrew his candidacy on October 29 and named Duterte as his substitute. A month later, Duterte formally announced his presidential bid and accepted Alan Peter Cayetano's offer to be his running mate; Duterte also named Sara as his substitute for Mayor of Davao City.
==== Supplements ==== Avocado–soybean unsaponifiables (ASU) is an extract made from avocado oil and soybean oil sold under many brand names worldwide as a dietary supplement and as a prescription drug in France. A 2014 Cochrane review found that while ASU might help relieve pain in the short term for some people with osteoarthritis, it does not appear to improve or maintain the health of affected joints. The review noted a high-quality, two-year clinical trial comparing ASU to chondroitin – which has uncertain efficacy in osteoarthritis – with no difference between the two agents. The review also found there is insufficient evidence of ASU safety. Only a few moderate-quality studies of Boswellia serrata showed small improvements in pain and function. Curcumin and s-adenosyl methionine (SAMe) showed little effect in improving pain. A 2009 Cochrane review recommended against the routine use of SAMe, as there has not been sufficient high-quality clinical research to prove its effect. A 2021 review found that hydroxychloroquine (HCQ) had no benefit in reducing pain and improving physical function in hand or knee osteoarthritis, and the off-label use of HCQ for people with osteoarthritis should be discouraged. There is no evidence for the use of colchicine for treating the pain of hand or knee arthritis. There is limited evidence to support the use of hyaluronan, methylsulfonylmethane, rose hip, capsaicin, or vitamin D.
A group of South American species formerly placed in the genus Datura are now placed in the distinct genus Brugmansia (Brugmansia differs from Datura in that it is woody (the species being shrubs or small trees) and has indehiscent fruits.) The solanaceous tribe Datureae, to which Datura and Brugmansia belong, has recently acquired a new, monotypic genus Trompettia J. Dupin, featuring the species Trompettia cardenasiana, which had hitherto been misclassified as belonging to the genus Iochroma. Datura specialists Ulrike Preissel and Hans-Georg Preissel accept only nine species of Datura, but Kew's Plants of the World Online lists the following 14 (out of which its related The Plant List does not include D. arenicola, D. lanosa and D. pruinosa as accepted spp.):
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.